Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
about
Neuroplasticity and the next wave of antidepressant strategiesPotential of Glutamate-Based Drug Discovery for Next Generation AntidepressantsKetamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacyRapid antidepressant actions of scopolamine: Role of medial prefrontal cortex and M1-subtype muscarinic acetylcholine receptorsHomer1/mGluR5 activity moderates vulnerability to chronic social stressThe role of leptin in central nervous system diseasesEmotional and cognitive dysregulation in schizophrenia and depression: understanding common and distinct behavioral and neural mechanismsInflammatory biomarkers as differential predictors of antidepressant responseVilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapyAdvancing understanding of executive function impairments and psychopathology: bridging the gap between clinical and cognitive approachesR-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effectsComparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depressionKetamine-induced brain activation in awake female nonhuman primates: a translational functional imaging model.Alterations in the inflammatory cytokines and brain-derived neurotrophic factor contribute to depression-like phenotype after spared nerve injury: improvement by ketamine.The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation.Mechanisms underlying the antidepressant response and treatment resistance.Glutamate and norepinephrine interaction: Relevance to higher cognitive operations and psychopathology.Psychiatric disorders: diagnosis to therapyAntidepressant Effects of Ketamine on Depression-like Behavior in Juvenile Mice after Neonatal Dexamethasone Exposure.Identifying novel interventional strategies for psychiatric disorders: integrating genomics, 'enviromics' and gene-environment interactions in valid preclinical models.Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeuticsThe role of ketamine in treatment-resistant depression: a systematic review.Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation.Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression.BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms.Beyond serotonin: newer antidepressants in the future.Recent insights into the mode of action of memantine and ketamineKetamine as a promising prototype for a new generation of rapid-acting antidepressants.Involvement of the catecholaminergic system on the antidepressant-like effects of Alpinia zerumbet in mice.Glutamate metabolism in major depressive disorderSpine synapse remodeling in the pathophysiology and treatment of depression.Glutamate modulators in the treatment of obsessive-compulsive disorder.Glutamatergic agents for OCD and related disordersEvidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in HumansKetamine Strengthens CRF-Activated Amygdala Inputs to Basal Dendrites in mPFC Layer V Pyramidal Cells in the Prelimbic but not Infralimbic Subregion, A Key Suppressor of Stress ResponsesThe effect of imipramine, ketamine, and zinc in the mouse model of depressionThe Antidepressant Effects of an mGlu2/3 Receptor Antagonist and Ketamine Require AMPA Receptor Stimulation in the mPFC and Subsequent Activation of the 5-HT Neurons in the DRN.Timosaponin derivative YY-23 acts as a non-competitive NMDA receptor antagonist and exerts a rapid antidepressant-like effect in miceGABAergic control of depression-related brain statesGene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress.
P2860
Q21129480-E8143EB4-DE5A-4C4B-A877-A6E987CBFA4DQ26782274-5A51D0AC-6526-4C2F-90F8-958B8D5B960AQ27024227-13C910A3-868A-4703-8757-664B32970C34Q27308009-5F636A60-01EC-4E57-9204-CB6F513E5B5BQ27311111-7E7C4E24-CDE5-466B-9B75-D577E6AA4A25Q28069664-A971F093-245C-4154-BB87-4C8306037730Q28073684-1CAC1BCB-6A3A-43F8-ADB8-1715E542EAC6Q28081799-4546EA6A-2CFF-474D-A624-6A74F3CEB216Q28083651-42893854-28E9-4EDB-8F51-5F79041C3BC5Q28083948-317C4841-ADCB-4EF5-9517-0E2905172C8DQ28266846-E9B830F1-4D22-4CE0-90F0-368B7E24DF45Q28277636-C76272E7-00E6-4E5E-AB96-D2D0743D8DE9Q30714646-B3DAD43E-E84F-4208-9235-547365AA4039Q30855337-8E097DFE-500F-42CB-9F5E-CDFB2EC9DC90Q33583121-F6F61583-B698-4719-A603-D3B9D9BF8914Q33814386-CF4C5231-6E36-40D4-BEF1-AC1620AAE5BEQ33836007-89C97A05-5F26-4D76-A0A5-75F9A531853CQ33922884-07EB1A5E-2E63-4EFD-BE31-998565FC69E1Q34129846-633D329D-83F7-4527-AAD9-254ABAF13E16Q34407170-308F4B70-E6D1-4412-BE88-CC6DB6CECFA4Q34444632-2AC24BEC-DC49-4582-AC4B-C101B65CEB38Q34449588-95555C8A-7F52-43BA-9DB6-69A56B902EE0Q34460057-4D8F04E0-1625-40E9-90BF-8E4ECB5F1B38Q34492381-2AA370AC-F871-4681-889C-C63DF621F872Q34499572-7EE085F7-E27E-41F3-9EB4-84250602121DQ34557706-3C535D99-7051-466D-8494-3412274551B0Q35054539-A95451DB-DE8A-4C47-806C-273D139402D9Q35547495-53F5557C-7E20-456F-8BF2-F1623B679B05Q35606297-1A4397F5-A2D1-4D5A-B2AB-2C34A3E631B3Q35756139-3D33E75C-6274-4500-BD44-511D763BADA4Q35836787-272E11FD-30B6-4C7A-A3C5-53963202555EQ35897264-171FDDC1-09EF-40B9-8180-1DDCD7BCF219Q35967025-F2C2A8DD-D412-49CF-A572-30C342E5E8F3Q35968145-EB14B139-2473-4B10-9493-8AF50FE5391DQ36184922-65D7A18A-9599-46C2-94B4-F62EB56C8D02Q36273782-944B6B67-63D9-4D9B-935B-C3F1B8F2841BQ36565640-64F6B430-17EB-424F-B96A-AFCC36E6FD46Q36579258-851F0970-82AC-462D-B963-C8A14DFB3352Q36668325-12C0DA19-CB21-45F1-B940-338A75EB274EQ36770623-1A0D2D61-7E02-49A9-81F3-A95C365AAD42
P2860
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
@en
type
label
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
@en
prefLabel
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
@en
P2093
P2860
P1476
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond.
@en
P2093
Gerard Sanacora
John H Krystal
Ronald S Duman
P2860
P304
P356
10.1016/J.BIOPSYCH.2013.03.026
P407
P577
2013-06-01T00:00:00Z